Assertio Holdings Acquisition by Zydus Lifesciences Finalized; Shares to Delist
Summary
Zydus Lifesciences has successfully completed its tender offer for Assertio Holdings, Inc., with the merger and subsequent delisting of Assertio shares expected today.
Key Events
-
Tender Offer Completed
Zara Merger Sub Inc., a subsidiary of Zydus Lifesciences, successfully completed its cash tender offer for all outstanding shares of Assertio Holdings, Inc. at $23.50 per share.
-
Minimum Condition Met
As of the expiration on June 15, 2026, 4,286,488 shares, representing approximately 66.32% of Assertio's outstanding shares, were validly tendered, satisfying the minimum condition for the acquisition.
-
Merger Imminent
The acquisition is expected to be completed on June 16, 2026, through a short-form merger, with Assertio becoming a wholly-owned subsidiary of Zydus Lifesciences.
-
Shares to be Delisted
Following the merger, Assertio's common stock will be delisted from the Nasdaq Capital Market, and its reporting obligations under the Exchange Act will be terminated.
Analysis
This filing confirms the successful completion of the tender offer by Zydus Worldwide DMCC to acquire Assertio Holdings, Inc. The minimum condition for the tender offer was met, with approximately 66.32% of Assertio's outstanding shares validly tendered. The acquisition will now proceed via a short-form merger, making Assertio a wholly-owned subsidiary of Zydus. This marks the final stage of Assertio's acquisition, leading to its delisting from the Nasdaq Capital Market and the cessation of its independent public trading.
At the time of this filing, ASRT was trading at $23.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $151.9M. The 52-week trading range was $8.61 to $23.50. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.